Latest Breaking News On - Zeneca chief executive pascal soriot - Page 13 : comparemela.com
UK COVID-19 Update: Eye of the Storm, Second Dose Jabs Begin
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
`Vaccine effective vs Covid variant – The Manila Times
manilatimes.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from manilatimes.net Daily Mail and Mail on Sunday newspapers.
Dr. Nicole Saphier discusses updated guidance, new coronavirus strain on ‘FOX & Friends Weekend.’
The Oxford COVID-19vaccine will be distributed across the U.K. starting January 4 if it is approved, according to a report by the Sunday Telegraph.
The British government has set a goal of vaccinating two million people within two weeks of starting distribution.
The plan includes doses from either the Oxford-AstraZeneca or Pfizer-BioNTech vaccines, according to the Telegraph. FILE - In this Saturday, July 18, 2020 file photo a general view of AstraZeneca offices and the corporate logo in Cambridge, England. AstraZeneca says late-stage trials of its COVID-19 vaccine were highly effective in preventing disease. A vaccine developed by AstraZeneca and the University of Oxford prevented 70% of people from developing the coronavirus in late-stage trials, the team reported Monday Nov. 23, 2020.(AP Photo/Alastair Grant, File)
AstraZeneca Stock Tumbles On $39 Billion Alexion Pharmaceuticals Takeover
investors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investors.com Daily Mail and Mail on Sunday newspapers.
UK TOP NEWS SUMMARY: AstraZeneca In USD39 Billion Deal For Alexion
Mon, 14th Dec 2020 10:58
(Alliance News) - The following is a summary of top news stories Monday.
COMPANIES
AstraZeneca, which is finalising a vaccine against Covid-19, said Saturday it was buying US biotech firm Alexion Pharmaceuticals for USD39 billion to boost its work on immunology. Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases, AstraZeneca Chief Executive Pascal Soriot said in a statement, announcing the year s biggest deal in the pharma sector. We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients, he said. Both boards have agreed to the cash-and-stock deal, which values Alexion at USD175 a share, a premium of 45% to the Boston-based company s closing